Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01570153 · ClinicalTrials.gov registry record

Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
100
Enrollment target

NCT01570153: Completed study, sponsored by Massachusetts General Hospital.

NCT01570153 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01570153 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
100 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the ability of a non-invasive monitor that measures how much fluid is in the body as well as various blood tests for their ability to predict worsening kidney function in patients with heart failure.

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2012-03
Est. Completion 2013-11
Massachusetts General Hospital

2,032 total trials

What the finished NCT01570153 record still lists

NCT01570153 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01570153 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01570153 about?

NCT01570153 is a clinical study titled "Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial". The purpose of this study is to evaluate the ability of a non-invasive monitor that measures how much fluid is in the body as well as various blood tests for their ability to predict worsening kidney function in patients with heart failure.

What is the current status of trial NCT01570153?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2012-03. Estimated completion is 2013-11.

Who is sponsoring clinical trial NCT01570153?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01570153, the US trial registry maintained by the National Library of Medicine. NCT01570153 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.